Treatment Patterns in Newly Diagnosed Multiple Myeloma Patients in Japan Using A Large-scale Claims Database： Retrospective Cohort Study

Jia Guan; Shiro Tanaka; Shuhei Yamada; Izumi Sato; Koji Kawakami

Return

Treatment Patterns in Newly Diagnosed Multiple Myeloma Patients in Japan Using A Large-scale Claims Database： Retrospective Cohort Study

VernacularTitle:Treatment Patterns in Newly Diagnosed Multiple Myeloma Patients in Japan Using A Large-scale Claims Database： Retrospective Cohort Study
Author: Jia GUAN ¹ ; Shiro TANAKA ² ; Shuhei YAMADA ² ; Izumi SATO ³ ; Koji KAWAKAMI ¹
Author Information

1. Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
2. Department of Clinical Biostatistics, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
3. Department of Quality and Patient Safety Management, Chiba Cancer Center, Chiba, Japan
Keywords: multiple myeloma; drug therapy; administrative claims; healthcare; retrospective studies; Japan
From:Japanese Journal of Pharmacoepidemiology 2020;25(2):43-53
CountryJapan
Language:English
Abstract: Objective: To describe the treatment patterns and time to next treatment (TTNT) in newly diagnosed multiple myeloma patients (MM) using a large-scale claims database in Japan.Design: Cohort studyMethods: The patients with newly diagnosed MM from 2008 to 2015 were classified into two groups: age <65 years, and age ≥65 years. Specific regimens and general regimens were identified with a complex algorithm considering interval of no therapy, additional and discontinued agents. Correspondingly, TTNT between the first- and second-line were measured among non-transplant patients with Kaplan-Meier method.Results: A total of 425 patients were eligible to participate in the analysis. The most common regimen for the treatment of MM was bortezomib-based regimens (52.9％ in the first-line, 28.2％ in later lines), followed by melphalan-prednisolone (27.1％ in the first-line, 12.9％ in later lines) and lenalidomide-based regimens (4.7％ in the first-line, 26.1％ in later lines). TTNT between the first- and second-line was 11.4 months and was seen to vary greatly with each regimen. A statistically longer TTNT was observed in subgroups of patients aged 65 years or over compared with patients aged younger than 65 years, but no statistical difference was found between conventional therapy and novel therapy.Conclusion: Based on the data from the study, patients with MM were commonly treated with novel agent-based regimens, especially bortezomib-based regimens. Between the first- and second-line therapies a relatively short TTNT was observed, indicating that therapies in clinical practice poorly complied with treatment guidelines.